Administration of combined dose of inhibitors of IGFBP3 activated kinases, EGFR, and sphingosine kinase (SphK) significantly inhibited triple-negative breast cancer cell growth in vitro and xenograft tumor models [100,101]. Here, IGFBP3 is linked to neoplasm.